Abstract
Purpose To compare the efficacy of Ex-PRESS implantation to trabeculectomy with mitomycin C, for maintaining low target intraocular pressure (IOP) in patients with open angle glaucoma.
Materials and Methods Patients were randomly assigned to receive Ex-PRESS implantation or trabeculectomy. Patients with IOP ≥ 15 mmHg were included in this study. Surgical success was defined according to three target mean IOP ranges (5 mmHg ≤ IOP ≤18 mmHg [criterion A], 5 mmHg ≤ IOP ≤15 mmHg [criterion B], and 5 mmHg ≤ IOP ≤12 mmHg [criterion C]) representing reductions of at least 20% below baseline on two consecutive follow-up visits 3 months post surgery.
Results A total of 73 patients, including 30 in the Ex-PRESS implantation group and 43 in the trabeculectomy group, were included in the study. The baseline IOP was 20.4 ± 4.9 mmHg in the Ex-PRESS implantation group and 21.9 ± 7.9 mmHg in the trabeculectomy group. There were no significant differences in baseline ocular or demographic characteristics between the two groups. There was no statistical difference in IOP every 6 months. After the 3-year follow-up, success rates were A) 60.0% and 60.2%, B) 45.7% and 58.1%, and C) 31.5% and 40.5% for the Ex-PRESS implantation and trabeculectomy groups, respectively. A greater number of glaucoma medications before surgery was associated with a higher failure rate in the trabeculectomy group but not the Ex-PRESS implantation group.
Conclusions Both procedures resulted in similar IOP reductions and success rates for low target IOP. The number of preoperative glaucoma medications was a risk factor for trabeculectomy failure.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
identifier University Hospital Medical Information Network UMIN000008981 date of access and registration, September 25, 2012
Clinical Protocols
https://www.umin.ac.jp/english/
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The institutional review board of Hiroshima University
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Registry This study was registered with the University Hospital Medical Information Network Clinical Trials Registry of Japan (identifier University Hospital Medical Information Network 000008981; date of access and registration, September 25, 2012
Data Availability
The research proposal stipulates that the data will be stored on a computer that is not connected to the Internet and will not be taken out.Data available on request from the author. The aurthor will provide data after reporting to the Ethics Committee of Hiroshima University Hospital.
